Alnylam Pharmaceuticals (ALNY) Goodwill & Intangibles (2009 - 2012)
Alnylam Pharmaceuticals' (ALNY) quarterly Goodwill & Intangibles came in at $145000.0 in Q3 2012, down 54.4% on a YoY basis from $318000.0 in Q4 2011, and down 22.87% quarter-over-quarter from $188000.0 in Q2 2012.
Analysis
Alnylam Pharmaceuticals (ALNY) Goodwill & Intangibles (2009 - 2012) Analysis & Trends
Alnylam Pharmaceuticals (ALNY) has reported Goodwill & Intangibles for 4 consecutive years, with $145000.0 the latest figure, recorded in Q3 2012.
- For the quarter ending Q3 2012, Goodwill & Intangibles fell 54.4% year-over-year to $145000.0; the trailing twelve-month figure through Sep 2012 stood at $145000.0 (down 54.4% YoY), and the FY2011 full-year result was $275000.0, down 38.62% from the prior year.
- Goodwill & Intangibles eased to $145000.0 in Q3 2012 per ALNY's latest filing, from $188000.0 in the prior quarter.
- Across five years, Goodwill & Intangibles topped out at $622000.0 in Q4 2009 and bottomed at $145000.0 in Q3 2012.
- Historically, Goodwill & Intangibles has averaged $365363.6 across 4 years, with a median of $361000.0 in 2011.
- The sharpest annual moves came in 2010 and 2012: Goodwill & Intangibles slipped 27.97% in 2010, then sank 54.4% in 2012.
- Over 4 years, Goodwill & Intangibles stood at $622000.0 in 2009, then retreated by 27.97% to $448000.0 in 2010, then tumbled by 38.62% to $275000.0 in 2011, then plunged by 47.27% to $145000.0 in 2012.
- According to Business Quant data, Goodwill & Intangibles over the past three periods registered $145000.0, $188000.0, and $231000.0 for Q3 2012, Q2 2012, and Q1 2012 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn |
| 10 | BioNTech SE | 26.24 Bn | 12.58 Bn | 10.00 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2012 | 145,000.00 |
| Jun 30, 2012 | 188,000.00 |
| Mar 31, 2012 | 231,000.00 |
| Dec 31, 2011 | 275,000.00 |
| Sep 30, 2011 | 318,000.00 |
| Jun 30, 2011 | 361,000.00 |
| Mar 31, 2011 | 405,000.00 |
| Dec 31, 2010 | 448,000.00 |
| Sep 30, 2010 | 491,000.00 |
| Jun 30, 2010 | 535,000.00 |
| Dec 31, 2009 | 622,000.00 |